AtriCure, Inc. (ATRC)
After hours:
- Zacks
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
- Business Wire
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with
- Business Wire
AtriCure to Announce First Quarter 2024 Financial Results
MASON, Ohio, April 10, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024.
